Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

NCT02718326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonproliferative Diabetic Retinopathy

Interventions

DRUG: Intravitreal aflibercept injection [IAI]
DRUG: Sham

Sponsor

Regeneron Pharmaceuticals